Review Papers Claim by Claim

Why this paper matters (short bullets)

• Comprehensive taxonomy and molecular detail of NK receptor classes (Ly49, KIR, CD94/NKG2, LILR, NKG2D family) with structural and signaling links (ITIM vs ITAM/DAP12/DAP10) Lanier review receptor taxonomy
• Clear statement that NK activation is analog (signal integration) not binary — inhibitory receptors act as rheostats modulating activating inputs (foundational for later immunometabolism and exhaustion studies) Missing‑self revisited

Critical appraisal — strengths

• Authoritative synthesis by a leader in the field; meticulous citation of primary structural, genetic, and functional studies (e.g., Ly49/H‑2 structural work, KIR–HLA co-crystals) Lanier core synthesis
• Balanced discussion of activating versus inhibitory receptor evolution, convergent solutions (Ly49 in rodents vs KIR in primates), and the physiological/clinical contexts (transplantation, viral immunity) Evolution & clinical context

Critical appraisal — limitations & blind spots (explicit)

1. Temporal limitation: review date (2004/2005) — misses major later advances (immunometabolism, NKG2D regulation by tumor shedding, NK cell memory, CAR‑NK engineering, checkpoint pathways TIGIT/PD-1 on NKs) and thus must be read as foundational but dated. Example later findings: tumor shedding of MICs and NKG2D downregulation (Groh et al., 2002; Steinle et al.) and immunometabolism work (e.g., TIGIT–HIF-1α glycolysis; recent 2025 studies) which modify mechanistic interpretation Temporal scope limitation
2. Functional inference vs causal proof: many receptor–ligand assignments (activating isoforms) were speculative or low-affinity at the time—Lanier notes that for some activating Ly49/KIR receptors physiological ligands were unresolved; later viral ligand studies (Ly49H–m157, KIR3DS1 hypotheses) provided stronger causality. Users must separate descriptive synthesis from experimentally proven interactions Caveats on activating receptors
3. Heterogeneity & translational gaps: species differences (Ly49 vs KIR) complicate extrapolation from mouse mechanistic models to humans — review explains this but cannot resolve it; modern readers should combine this review with recent human-focused studies (e.g., KIR haplotype clinical impact literature) Species extrapolation caution

Concrete, practical takeaways for scientists

• Use Lanier 2005 as canonical background for NK receptor classification and signaling motifs (ITIM/ITAM/DAP12/DAP10) when designing receptor/adapter experiments; cite it for the architecture and early hypotheses.
• When testing activating receptor function, include inflammatory cytokines (IL‑12/IL‑18/IL‑15) and consider co‑receptor context — Lanier notes activating receptors can be overridden or unmasked by cytokines.
• For translational applications (transplant, tumor immunology), complement Lanier's conceptual model with newer studies on immunometabolism, ligand shedding, checkpoint receptors (TIGIT, PD-1) and engineered NK therapies (CAR‑NK/CREM/IL‑15 modulation) to build mechanistic and clinical pipelines.

Selective curated citations (to follow up)

• Lanier LL. NK CELL RECOGNITION — foundational review of receptor families and signaling paradigms Lanier (2005) Review
• Examples of later, complementary work to consult (NKG2D ligand tumor shedding; viral evasion; immunometabolism/TIGIT): Groh et al. (MICA/soluble MIC attenuate NKG2D) and modern immunometabolism/TIGIT–HIF literature (see 2025 TIGIT/HIF work) — recommended to update mechanistic models beyond Lanier's timeframe Post-2005 updates (examples)

How to use this review in your work (short practical guide)

1. Read Lanier 2005 for receptor taxonomy and signaling motifs; extract candidate receptors/adapters for experimental panels.
2. Cross-check any activating receptor claims with subsequent functional ligand identifications (e.g., viral ligands) and binding affinity data.
3. If designing translational NK therapies, incorporate more recent studies (post‑2005) on ligand shedding, metabolic checkpoints, and CAR‑NK engineering before choosing targets or biomarkers.